Cantor Fitzgerald upgraded shares of Immuneering (NASDAQ:IMRX – Free Report) to a strong-buy rating in a research report sent to investors on Wednesday, MarketBeat Ratings reports. The brokerage currently has $17.00 price objective on the stock.
Several other equities research analysts have also issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immuneering in a research note on Wednesday, June 24th. Wall Street Zen lowered Immuneering from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. Chardan Capital reissued a “buy” rating and set a $20.00 price target on shares of Immuneering in a research report on Tuesday, May 19th. Finally, Oppenheimer restated an “outperform” rating on shares of Immuneering in a research note on Monday, June 1st. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $16.57.
Check Out Our Latest Research Report on Immuneering
Immuneering Stock Up 8.4%
Immuneering (NASDAQ:IMRX – Get Free Report) last announced its earnings results on Friday, May 15th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.09. Equities analysts anticipate that Immuneering will post -1.12 EPS for the current fiscal year.
Hedge Funds Weigh In On Immuneering
Several large investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd bought a new position in Immuneering in the 4th quarter valued at about $33,000. Levin Capital Strategies L.P. bought a new position in shares of Immuneering during the first quarter worth approximately $53,000. Mercer Global Advisors Inc. ADV acquired a new stake in Immuneering during the 3rd quarter worth approximately $70,000. SummitTX Capital L.P. bought a new stake in Immuneering in the 4th quarter valued at $69,000. Finally, Ausdal Financial Partners Inc. bought a new stake in Immuneering in the 4th quarter valued at $72,000. 67.65% of the stock is owned by institutional investors.
About Immuneering
Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.
The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.
Recommended Stories
- Five stocks we like better than Immuneering
- Sony Is Going All-Digital—But Investors Should Watch This Instead
- Scotiabank Sees a New Growth Story for Cloudflare
- A Market Panic Just Discounted the AI Highway’s Tollbooth
- Why Exxon Could Be the Market’s Next Big Comeback Stock
Receive News & Ratings for Immuneering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuneering and related companies with MarketBeat.com's FREE daily email newsletter.
